Search results for "CYP3A4"

showing 10 items of 30 documents

Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury

2017

Drug-induced liver injury (DILI) has a considerable impact on human health and is a major challenge in drug safety assessments. DILI is a frequent cause of liver injury and a leading reason for post-approval drug regulatory actions. Considerable variations in the expression levels of both cytochrome P450 (CYP) and conjugating enzymes have been described in humans, which could be responsible for increased susceptibility to DILI in some individuals. We herein explored the feasibility of the combined use of HepG2 cells co-transduced with multiple adenoviruses that encode drug-metabolising enzymes, and a high-content screening assay to evaluate metabolism-dependent drug toxicity and to identify…

0301 basic medicineDrugCYP2B6Drug-induced liver injuryHealth Toxicology and Mutagenesismedia_common.quotation_subjectPopulationDrug Evaluation PreclinicalPharmacologyToxicologyHepatotoxicity mechanismsGene Expression Regulation EnzymologicOrgan Toxicity and MechanismsAdenoviridae03 medical and health sciences0302 clinical medicineCYPToxicity TestsHumansCytochrome P450 Family 2educationmedia_commonMembrane Potential Mitochondrialeducation.field_of_studyCYP3A4biologyCytochrome P450IdiosyncrasyHep G2 CellsGeneral MedicineCYP2E1Recombinant ProteinsHigh-Throughput Screening Assays030104 developmental biology030220 oncology & carcinogenesisInactivation MetabolicToxicityCell modelbiology.proteinChemical and Drug Induced Liver InjuryReactive Oxygen SpeciesDrug metabolism
researchProduct

In silico and in vitro prediction of the toxicological effects of individual and combined mycotoxins.

2018

3-Acetyldeoxynivalenol (3-AcDON) and 15-acetyldeoxynivalenol (15-AcDON) are converted to deoxynivalenol (DON) in vivo and their simultaneous presence may increase DON intake. Mixtures of DON and its derivatives are a public health concern. In this study DON, 3-AcDON and 15-AcDON were evaluated in vitro and in silico. The in vitro cytotoxicity of DON and its derivatives individually and combined was determined by the Neutral Red (NR) assay in human hepatocarcinoma (HepG2) cells. The concentrations tested were from 1.25 to 15 μM (DON) and from 0.937 to 7.5 μM (DON derivatives). The IC50 values were from >15 to 2.55 μM (DON), from 1.77 to 1.02 μM (3-AcDON), and from 4.05 to 1.68 μM (15-AcDON).…

0301 basic medicineNeutral redCell SurvivalIn silicoComplex MixturesIn Vitro TechniquesToxicologyExcretion03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500404 agricultural biotechnologyIn vivoCytochrome P-450 CYP3AHumansComputer SimulationFood scienceMycotoxinCYP3A4Dose-Response Relationship DrugChemistry04 agricultural and veterinary sciencesGeneral MedicineHep G2 CellsMycotoxins040401 food scienceIn vitro030104 developmental biologyGastrointestinal AbsorptionToxicityTrichothecenesFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Metabolism and Bioactivation of Corynoline With Characterization of the Glutathione/Cysteine Conjugate and Evaluation of Its Hepatotoxicity in Mice

2018

Corynoline (CRL), an isoquinoline alkaloid, is the major constituent derived from Corydalis bungeana Herba, which is a well-known Chinese herbal medicine widely used in many prescriptions. The purpose of this study was to comprehensively investigate the metabolism and bioactivation of CRL, and identify the CYP450 isoforms involved in reactive ortho-benzoquinone metabolites formation and evaluate its hepatotoxicity in mice. Here, high resolution and triple quadrupole mass spectrometry were used for studying the metabolism of CRL. Three metabolites (M1-M3) and four glutathione conjugates (M4-M7) of CRL ortho-benzoquinone reactive metabolite were found in vitro using rat and human liver micros…

0301 basic medicinehepatotoxicityCorynolinePharmacology03 medical and health scienceschemistry.chemical_compoundPharmacology (medical)corynolineCYP450 enzymesOriginal Researchmass spectrometryPharmacologybioactivationCYP3A4Alkaloidlcsh:RM1-950fungifood and beveragesMetabolismGlutathionelcsh:Therapeutics. Pharmacology030104 developmental biologychemistryToxicityMicrosomemetabolismCysteineFrontiers in Pharmacology
researchProduct

Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis

2018

Hepatic vitamin D receptor (VDR) expression is increased in patients with nonalcoholic fatty liver (NAFL) and is required for liver steatosis in an NAFL mouse model. However, how hepatocyte VDR is involved in setting up steatosis remains unclear. The authors transduced human hepatocyte-derived cells with an adenoviral vector encoding human VDR and found that angiopoietin-like protein 8 (ANGPTL8) expression was increased upon VDR activation by vitamin D or lithocholic acid. The mRNA levels of hepatic VDR- and vitamin D-related genes [cytochrome P450 (CYP) 2R1, CYP27A1, and CYP3A4] were higher in NAFL patients compared with normal liver subjects. Noteworthy, hepatic ANGPTL8 mRNA and protein l…

AdultMale0301 basic medicinemedicine.medical_specialtyLithocholic acidPeptide HormonesFatty Acids NonesterifiedCalcitriol receptorPathology and Forensic Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAngiopoietin-Like Protein 8Non-alcoholic Fatty Liver DiseaseInternal medicineCYP27A1medicineHumansInsulinCells CulturedTriglyceridesGene knockdownCYP3A4Fatty liverMiddle Agedmedicine.diseaseAngiopoietin-like Proteins030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationchemistryCase-Control StudiesHepatocyteHepatocytesReceptors CalcitriolFemale030211 gastroenterology & hepatologySteatosisThe American Journal of Pathology
researchProduct

Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity.

2001

CYP activity and protein contents have been measured in human liver using different techniques. In contrast, CYP mRNA data are scarce and the relationships between CYP mRNA contents and activities have not been established. These studies deserve further attention because mRNA determinations by RT-PCR require a very small amount of material (e.g., liver needle biopsy) and could provide important data regarding CYP expression regulation. In this study we measured in 12 human liver samples the mRNA contents of 10 CYPs by quantitative RT-PCR and the metabolic activities using specific substrates. mRNA contents and activities showed high correlation coefficients for CYP1A1, CYP1A2, CYP3A4, CYP2D…

AdultMaleCYP2B6BiophysicsGene Expressiondigestive systemBiochemistryCytochrome P-450 Enzyme SystemHumansheterocyclic compoundsRNA MessengerCYP2A6Molecular BiologyCYP2C9AgedMessenger RNAbiologyCYP3A4CYP1A2respiratory systemCYP2E1Middle AgedMolecular biologyEnzyme assayIsoenzymesBiochemistryLiverbiology.proteinMicrosomes LiverFemaleArchives of biochemistry and biophysics
researchProduct

Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects

2007

Aripiprazole, a novel antipsychotic drug, is metabolized by CYP3A4 and CYP2D6 forming mainly its active metabolite dehydroaripiprazole. In this study, aripiprazole and dehydroaripiprazole serum levels of psychiatric patients were measured and related to dose, comedication, and clinical effects including therapeutic and side effects. Patients were treated with mean doses of 20 +/- 8 mg/day of aripiprazole (median 15 mg, range 7.5-60 mg). Serum levels correlated significantly with the dose (r = 0.419; P0.01), with a mean value of aripiprazole of 214 +/- 140 ng/ml. Mean concentrations of the active metabolite dehydroaripiprazole amounted to 40% of the parent compound. Comedication with CYP3A4 …

AdultMaleCYP2D6AripiprazoleQuinolonesPharmacologydigestive systemPiperazinesCytochrome P-450 CYP3AHumansMedicineAntipsychotic drugskin and connective tissue diseasesDehydroaripiprazoleBiological PsychiatryActive metaboliteAgedCYP3A4medicine.diagnostic_testbusiness.industryMiddle AgedPsychiatry and Mental healthCytochrome P-450 CYP2D6Therapeutic drug monitoringSchizophreniaFemaleAripiprazolebusinessAntipsychotic Agentsmedicine.drugThe World Journal of Biological Psychiatry
researchProduct

Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment

2011

In a number of adverse drug reactions leading to hepatotoxicity, drug metabolism is thought to be involved by the generation of reactive metabolites from non-toxic drugs. The use of hepatoma cell lines, such as HepG2 cell line, for the evaluation of drug-induced hepatotoxicity is hampered by their low cytochrome P450 expression which makes impossible the study of the toxicity produced by bioactivable compounds. Genetically manipulated cells constitute promising tools for hepatotoxicity applications. HepG2 cells were simultaneously transfected with recombinant adenoviruses encoding CYP1A2, CYP2C9 and CYP3A4 to confer them drug-metabolic competence. Upgraded cells (Adv-HepG2) were highly able…

Aflatoxin B1Cell SurvivalGenetic VectorsPharmacologyTransfectionToxicologyModels BiologicalCitric AcidCalcium in biologyAdenoviridaeCytochrome P-450 CYP1A2RotenoneCytochrome P-450 CYP3AHumansViability assayCytochrome P-450 CYP2C9Membrane Potential MitochondrialCYP3A4biologyChemistryCYP1A2Cytochrome P450Hep G2 CellsGeneral MedicineTransfectionBiochemistryHigh-content screeningbiology.proteinCalciumAryl Hydrocarbon HydroxylasesChemical and Drug Induced Liver InjuryDrug metabolismToxicology in Vitro
researchProduct

Evaluation of Cytochrome P450 Activities in Human Hepatocytes In Vitro

2011

Major hepatic cytochrome P450 activities (CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) can be simultaneously examined in human hepatocytes by incubation with a cocktail of multiple specific probes. Cocktail strategy in combination with mass spectrometry is shown to be a robust, fast, and sensitive procedure for P450 activity assessment. This procedure allows a drastic reduction of the number of cells required in the assay and sample analysis time and increases throughput and reproducibility. Major applications of the probe cocktail strategy are P450 phenotyping of hepatocytes and induction studies.

CYP2D6CYP2B6biologyBiochemistryCYP3A4ChemistryCYP1A2biology.proteinfood and beveragesCytochrome P450CYP2E1CYP2A6In vitro
researchProduct

Pharmacokinetic interaction between efavirenz and ketoconazole in rats

2009

It is well known that efavirenz and ketoconazole act as an inducer and inhibitor of CYP3A4, respectively. As a result of these actions, co-administration of these drugs may result in changes in the pharmacoki- netic parameters of one or both of them. 2. Duodenum-cannulated rats have been used to compare the effect of intraduodenal (KC i.d. ) and intrave- nous administration of ketoconazole (KC i.v. ) on the pharmacokinetics of efavirenz after intraduodenal administration, as well as the potential effect of efavirenz as a CYP450 inducer on ketoconazole phar - macokinetic profile. 3. While KC i.v. did not show any significant effect on efavirenz pharmacokinetic profile, KC i.d. increased sig-…

CyclopropanesMalemedicine.medical_specialtyAntifungal AgentsEfavirenzAnti-HIV AgentsHealth Toxicology and MutagenesisPharmacologyToxicologyBiochemistryEnteral administrationDrug Administration SchedulePeak concentrationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemPharmacokineticsimmune system diseasesInternal medicinemedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsDrug InteractionsInducerRats WistarPharmacologyCYP3A4Chemistryvirus diseasesGeneral MedicineBenzoxazinesRatsKetoconazoleEndocrinologyAlkynesKetoconazolePharmacokinetic interactionmedicine.drugXenobiotica
researchProduct

Coordinated induction of drug transporters and phase I and II metabolism in human liver slices

2008

Although regulation of phase I drug metabolism in human liver is relatively well studied, the regulation of phase II enzymes and of drug transporters is incompletely characterized. Therefore, we used human liver slices to investigate the PXR, CAR and AhR-mediated induction of drug transporters and phase I and II metabolic enzymes. Precision-cut human liver slices were incubated for 5 or 24 h with prototypical inducers: phenobarbital (PB) (50 mu M) for CAR, beta-naphthoflavone (BNF) (25 mu M) for AhR, and rifampicin (RIF) (10 mu M) for PXR, and gene expression of the phase I enzymes CYP1A1, 1A2, 3A4, 3A5, 2136, 2A6, the phase II enzymes UGT1A1 and 1A6, and the transporters MRP2, MDR1, BSEP, …

DIFFERENTIAL REGULATIONQUANTITATIVE RT-PCRRAT-LIVERGene ExpressionPharmaceutical Sciencedrug transportersIn Vitro TechniquesPharmacologydigestive systemCytochrome P-450 Enzyme SystemUDP-GLUCURONOSYLTRANSFERASE 1A1Constitutive androstane receptorHumansSTELLATE CELL ACTIVATIONEnzyme inducerinductionliver slicesCONSTITUTIVE ANDROSTANE RECEPTORchemistry.chemical_classificationPregnane X receptorbiologyCYP3A4Multidrug resistance-associated protein 2TransporterPRIMARY HUMAN HEPATOCYTESMetabolic Detoxication Phase IIdrug metabolismEnzymeLiverPharmaceutical PreparationsBiochemistrychemistryEnzyme Inductionbiology.proteinMetabolic Detoxication Phase IPREGNANE-X-RECEPTORCarrier ProteinsPROTOTYPICAL INDUCERSDrug metabolismBILE-ACIDEuropean Journal of Pharmaceutical Sciences
researchProduct